BR112019026080A8 - Composições e métodos para modular o crescimento capilar - Google Patents

Composições e métodos para modular o crescimento capilar

Info

Publication number
BR112019026080A8
BR112019026080A8 BR112019026080A BR112019026080A BR112019026080A8 BR 112019026080 A8 BR112019026080 A8 BR 112019026080A8 BR 112019026080 A BR112019026080 A BR 112019026080A BR 112019026080 A BR112019026080 A BR 112019026080A BR 112019026080 A8 BR112019026080 A8 BR 112019026080A8
Authority
BR
Brazil
Prior art keywords
hair growth
methods
compositions
modulate hair
modulate
Prior art date
Application number
BR112019026080A
Other languages
English (en)
Other versions
BR112019026080A2 (pt
Inventor
e lowry William
E Jung Michael
CHRISTOFK Heather
Liu Xiaoguang
Flores Aimee
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of BR112019026080A2 publication Critical patent/BR112019026080A2/pt
Publication of BR112019026080A8 publication Critical patent/BR112019026080A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A61K8/492—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid having condensed rings, e.g. indol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/69—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/69—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine
    • A61K8/70—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine containing perfluoro groups, e.g. perfluoroethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/41—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by carboxyl groups, other than cyano groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/57—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/535—Organo-phosphoranes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)

Abstract

A presente invenção refere-se a compostos que são capazes de inibir o transportador de piruvato mitocondrial e promover o crescimento capilar. A divulgação refere-se ainda a métodos para promover o crescimento capilar ou tratar afecções ou distúrbios que afetam o crescimento capilar, tais como calvície ou alopecia.
BR112019026080A 2017-06-30 2018-06-29 Composições e métodos para modular o crescimento capilar BR112019026080A8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762527775P 2017-06-30 2017-06-30
US62/527,775 2017-06-30
US201862654095P 2018-04-06 2018-04-06
US62/654,095 2018-04-06
PCT/US2018/040385 WO2019006359A1 (en) 2017-06-30 2018-06-29 COMPOSITIONS AND METHODS FOR MODULATION OF HAIR GROWTH

Publications (2)

Publication Number Publication Date
BR112019026080A2 BR112019026080A2 (pt) 2020-06-30
BR112019026080A8 true BR112019026080A8 (pt) 2022-11-22

Family

ID=64742233

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019026080A BR112019026080A8 (pt) 2017-06-30 2018-06-29 Composições e métodos para modular o crescimento capilar

Country Status (15)

Country Link
US (4) US11312714B2 (pt)
EP (1) EP3644989A4 (pt)
JP (2) JP7221227B2 (pt)
KR (2) KR20240033119A (pt)
CN (2) CN110944634A (pt)
AR (1) AR114075A1 (pt)
AU (2) AU2018294351B2 (pt)
BR (1) BR112019026080A8 (pt)
CA (1) CA3067746A1 (pt)
CL (1) CL2019003886A1 (pt)
EA (1) EA202090179A1 (pt)
IL (2) IL305317A (pt)
MX (2) MX2019015475A (pt)
PE (1) PE20200743A1 (pt)
WO (1) WO2019006359A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102440809B1 (ko) 2017-02-24 2022-09-05 더 리전트 오브 더 유니버시티 오브 캘리포니아 Mpc 저해제를 사용하여 모발 성장을 촉진하는 조성물 및 방법
KR20240033119A (ko) 2017-06-30 2024-03-12 더 리전트 오브 더 유니버시티 오브 캘리포니아 모발 성장을 조절하기 위한 조성물 및 방법
CN112153957B (zh) * 2018-04-13 2023-12-26 北卡罗来纳州立大学 微针贴剂促进毛发生长的用途
SG11202106471RA (en) * 2019-01-02 2021-07-29 Univ California Compositions and methods for modulating hair growth
IL293584A (en) * 2019-12-20 2022-08-01 Univ California Synthesis of compounds to promote hair growth
FR3105222B1 (fr) * 2019-12-20 2022-06-03 Nunii Laboratoire Inhibiteur du transporteur MCT7/SLC16A6 pour son utilisation pour la régulation de la pigmentation cutanée et une composition comprenant ledit inhibiteur
US20230227406A1 (en) * 2020-06-12 2023-07-20 Rekindle Therapeutics Inc. Modulators of e3 ligases
US20230322765A1 (en) * 2020-06-30 2023-10-12 The Regents Of The University Of California Compositions and methods for modulating hair growth
EP4172158A4 (en) * 2020-06-30 2024-01-10 The Regents of the University of California COMPOSITIONS AND METHODS FOR MODULATING HAIR GROWTH
AU2022425460A1 (en) 2021-12-29 2024-07-18 Pelage Pharmaceuticals, Inc. Compounds for treatment of hair loss
KR20240130763A (ko) * 2021-12-29 2024-08-29 펠라지 파마슈티컬스, 인크. 탈모 치료용 화합물
WO2023191515A1 (ko) * 2022-03-29 2023-10-05 연세대학교 산학협력단 인디루빈 유도체 및 대사활성화제를 포함하는 탈모 방지 또는 발모 촉진용 조성물
WO2024145369A1 (en) * 2022-12-27 2024-07-04 Pelage Pharmaceuticals, Inc. Compounds for treatment of hair loss
CN116251086A (zh) * 2023-02-15 2023-06-13 江西中医药大学 乳酸及其衍生物在促毛发生长及缓解脱发中的应用

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
JPH0235746B2 (ja) 1983-03-07 1990-08-13 Sagami Chem Res 33chikantetorafuruoroindoorujudotai
US4680413A (en) * 1986-01-17 1987-07-14 Nippon Soda Co., Ltd. Process for the production of 3-phenyl-4-cyanopyrroles
GB8913708D0 (en) * 1989-06-14 1989-08-02 Unilever Plc Cosmetic composition
GB9014221D0 (en) 1990-06-26 1990-08-15 Janssen Pharmaceutica Nv Method of treating alopecia
GB9023585D0 (en) 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
GB9226855D0 (en) * 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
GB9412719D0 (en) 1994-06-24 1994-08-17 Erba Carlo Spa Substituted azaindolylidene compounds and process for their preparation
JPH09176162A (ja) 1995-12-22 1997-07-08 Toubishi Yakuhin Kogyo Kk チアゾリジンジオン誘導体及びその製造法並びにそれを含む医薬組成物
US6110973A (en) 1998-01-29 2000-08-29 Sepracor Methods for treating obesity and weight gain using optically pure (-)-bupropion
FR2796274B1 (fr) 1999-07-16 2001-09-21 Oreal Utilisation de l'acide 4,6-dimethoxy-indole 2-carboxylique ou de ses derives pour stimuler ou induire la pousse des cheveux et/ou stopper leur chute
US6416777B1 (en) 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
DE60127827T2 (de) 2000-02-23 2007-12-27 Orentreich Foundation For The Advancement Of Science, Inc. Verwendung von einem insulin-sensibilisator in der behandlung von alopecia
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
CA2452558C (en) 2001-07-17 2009-12-22 N-Gene Research Laboratories Inc. A synergistic pharmaceutical combination for the prevention or treatment of diabetes
EP1605967A1 (en) * 2003-03-13 2005-12-21 Novo Nordisk A/S Novel nph insulin preparations
US20050277784A1 (en) 2004-06-14 2005-12-15 Wyeth Processes for the preparation of 2-cyano-3-naphthalene-1-yl-acrylic acid alkyl or benzyl esters
MY144903A (en) 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
EP1791535B1 (en) 2004-09-17 2008-07-30 BioMAS Ltd. Novel tellurium compounds and their use as immunomodulators
DK1848431T3 (en) 2005-02-09 2016-04-18 Santen Pharmaceutical Co Ltd LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS
AU2006339311A1 (en) 2005-06-07 2007-09-07 Foamix Ltd. Antibiotic kit and composition and uses thereof
AU2006261993B2 (en) 2005-06-22 2011-11-17 Plexxikon, Inc. Pyrrolo (2, 3-B) pyridine derivatives as protein kinase inhibitors
GB0525337D0 (en) 2005-12-13 2006-01-18 Novartis Ag Organic compounds
US8343962B2 (en) 2006-03-06 2013-01-01 Nuvo Research Inc. Topical formulation
US9308181B2 (en) 2006-03-06 2016-04-12 Nuvo Research Inc. Topical formulations, systems and methods
PE20080767A1 (es) 2006-08-31 2008-08-08 Smithkline Beecham Corp Derivados de acido 1-indol-2-carboxilico como moduladores de ppar
US20080064765A1 (en) 2006-09-11 2008-03-13 Jacob Birnbaum Novel hair growth compositions and methods for treating hair loss or related claims
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
WO2009030257A1 (en) 2007-09-05 2009-03-12 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Methods and compounds for treating diseases caused by reactive oxygen species
WO2011123788A1 (en) 2010-04-01 2011-10-06 Duke University Compositions and methods for the treatment of cancer
CA2819859A1 (en) 2010-12-06 2012-06-14 Follica, Inc. Methods for treating baldness and promoting hair growth
CA2860187C (en) * 2011-12-22 2020-11-10 Connexios Life Sciences Pvt. Ltd. Cyclic amide derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase and uses thereof
EP2847356A4 (en) * 2012-05-10 2015-08-05 Univ Utah Res Found COMPOSITIONS AND METHODS FOR MODULATING THE ACTIVITY OF A MITOCHONDRIAL PYRUVATE CARRIER
WO2013185214A1 (en) 2012-06-11 2013-12-19 Universite Laval Pla2g7/lp-pla2 as biomarker and therapeutic target in the prevention and treatment of calcific aortic valve disease
US9452959B2 (en) 2012-06-12 2016-09-27 The Regents Of The University Of California Fluorination of aryl compounds
WO2014207213A1 (en) 2013-06-28 2014-12-31 Medizinische Universität Innsbruck Novel inhibitors of protein kinase c epsilon signaling
US20160250249A1 (en) * 2013-10-03 2016-09-01 Inserm ( Institute National De Lasanté Et De La Re Cherche Médicale) Methods and pharmaceutical compositions for modulating autophagy in a subject in need thereof
US9636340B2 (en) 2013-11-12 2017-05-02 Ayyappan K. Rajasekaran Kinase inhibitors
CN105934248A (zh) 2014-01-24 2016-09-07 融合生命科学公司 取代的吡咯并吡啶和吡咯并吡嗪用于治疗癌症或炎性疾病
WO2017196936A1 (en) 2016-05-12 2017-11-16 Regents Of The University Of Minnesota Indole and indazole cyanocinnamate compounds and therapeutic uses thereof
WO2018039615A1 (en) 2016-08-26 2018-03-01 The Regents Of The University Of California Hair follicle stem cell activation and hair growth
WO2018039612A1 (en) 2016-08-26 2018-03-01 The Regents Of The University Of California Compositions and methods for promoting hair growth with mpc1 inhibitors
CA3047589A1 (en) 2016-12-22 2018-06-28 Mavupharma, Inc. Phosphodiesterase inhibitors and methods of microbial treatment
KR102440809B1 (ko) 2017-02-24 2022-09-05 더 리전트 오브 더 유니버시티 오브 캘리포니아 Mpc 저해제를 사용하여 모발 성장을 촉진하는 조성물 및 방법
CN106880693A (zh) 2017-03-22 2017-06-23 广州国草夏方生物科技有限公司 一种治疗脂溢性脱发的生发液组合物及其制备方法
KR20240033119A (ko) 2017-06-30 2024-03-12 더 리전트 오브 더 유니버시티 오브 캘리포니아 모발 성장을 조절하기 위한 조성물 및 방법
CA3077359A1 (en) 2017-09-29 2019-04-04 The Regents Of The University Of California Compositions and methods for modulating hair growth
SG11202106471RA (en) 2019-01-02 2021-07-29 Univ California Compositions and methods for modulating hair growth
WO2020150146A1 (en) 2019-01-14 2020-07-23 The Regents Of The University Of California Compositions and methods for treating cardiac injury
US20220079899A1 (en) 2019-01-14 2022-03-17 The Regents Of The University Of California Compositions and methods for treating ocular conditions
IL293584A (en) 2019-12-20 2022-08-01 Univ California Synthesis of compounds to promote hair growth
US20230322765A1 (en) 2020-06-30 2023-10-12 The Regents Of The University Of California Compositions and methods for modulating hair growth
EP4172158A4 (en) 2020-06-30 2024-01-10 The Regents of the University of California COMPOSITIONS AND METHODS FOR MODULATING HAIR GROWTH

Also Published As

Publication number Publication date
AR114075A1 (es) 2020-07-15
IL305317A (en) 2023-10-01
MX2022007823A (es) 2022-07-19
CL2019003886A1 (es) 2020-05-22
IL271443A (en) 2020-01-30
JP2023061995A (ja) 2023-05-02
US20200157093A1 (en) 2020-05-21
AU2023201669A1 (en) 2023-04-13
US20230114220A1 (en) 2023-04-13
NZ759233A (en) 2023-08-25
US20220153738A1 (en) 2022-05-19
JP7221227B2 (ja) 2023-02-13
US11312714B2 (en) 2022-04-26
KR20240033119A (ko) 2024-03-12
AU2018294351A1 (en) 2019-12-05
KR20200022480A (ko) 2020-03-03
AU2018294351B2 (en) 2022-12-22
PE20200743A1 (es) 2020-07-24
US11472804B2 (en) 2022-10-18
CA3067746A1 (en) 2019-01-03
US11787804B2 (en) 2023-10-17
WO2019006359A1 (en) 2019-01-03
EP3644989A4 (en) 2021-07-14
JP2020526484A (ja) 2020-08-31
IL271443B1 (en) 2023-09-01
US20240025895A1 (en) 2024-01-25
KR102642823B1 (ko) 2024-03-04
CN116120314A (zh) 2023-05-16
EA202090179A1 (ru) 2020-04-24
BR112019026080A2 (pt) 2020-06-30
CN110944634A (zh) 2020-03-31
IL271443B2 (en) 2024-01-01
MX2019015475A (es) 2020-02-19
EP3644989A1 (en) 2020-05-06

Similar Documents

Publication Publication Date Title
BR112019026080A8 (pt) Composições e métodos para modular o crescimento capilar
BR112021012829A2 (pt) Composições e métodos para modular o crescimento capilar
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
CO2019006622A2 (es) Derivados de pirazol como inhibidores de malt1
CL2019001711A1 (es) Composiciones y métodos para inhibir la acción de la arginasa.
BR112015032595A2 (pt) inibidores de ido
BR112017020999A2 (pt) inibidores de indolamina-2,3-dioxigenase para o tratamento de câncer
UY37018A (es) Inhibidores bicíclicos de pad4
BR112018068851A2 (pt) composto da fórmula, composição, métodos de combate ou controle de pragas invertebradas, de proteção de plantas e de tratamento ou proteção de animais, semente e uso de composto
BR112016010982A2 (pt) Composições estabilizantes de ureia e nitrogênio
PH12015502028A1 (en) Ido inhibitors
BR112018003588A2 (pt) compostos e composições úteis para tratamento de distúrbios relacionados ao ntrk
CL2016000045A1 (es) Compuestos de n,6-bis(aril o heteroaril)-1,3,5-triazin-2,4-diamina como inhibidores de idh2 mutantes para el tratamiento de cáncer.
MX2016000295A (es) Inhibidores de indoleamina 2,3-dioxigenasa (ido).
BR112015021999A8 (pt) inibidores de indoleamina 2,3-dioxigenase (ido), seus usos, composição farmacêutica, e método para inibir a atiavidade de indoleamina 2,3-dioxigenase
BR112016014412A2 (pt) Compostos de diaminopirimidil substituído, composições do mesmo, e métodos de tratamento com o mesmo
CR20160229A (es) Inhibidires de bromodominio
BR112017021167A2 (pt) composto, método de tratamento de câncer, e processo para preparar o composto de fórmula i
BR112017006705A2 (pt) inibidores de biossíntese de sulfato de heparan para o tratamento de doenças
BR112016014020A8 (pt) moduladores de tetra-hidropiridopirazinas de gpr6.
UY37017A (es) Inhibidores aza-bencimidazol de pad4
BR112018014015A2 (pt) derivados de tioidantoína substituídos como antagonistas do receptor de androgênio
BR112017017349A2 (pt) composto, composição, método para tratar um distúrbio
PH12020500300A1 (en) Compositions and methods for modulating hair growth
BR112018014590A2 (pt) formulações/composições compreendendo um inibidor de btk

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]